Active Ingredient(s): Daclatasvir
FDA Approved: * July 24, 2015
Category: Hepatitis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Daklinza Overview

Daclatasvir, sold under the trade name Daklinza, is a medication used in combination with other medications to treat hepatitis C (HCV).[1] The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis.[3] In significant difference to previous HCV therapies, Daclatasvir has the advantage of being taken orally in low application rates of normally 60 mg once daily with...

Read more Daklinza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daclatasvir

Recent Daklinza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 30mg, 60mg, 90mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Daklinza: (3 results)

Sorted by National Drug Code
  • 0003-0011 Daklinza 90 mg Oral Tablet by E.r. Squibb & Sons, L.L.C.
  • 0003-0213 Daklinza 30 mg Oral Tablet by E.r. Squibb & Sons, L.L.C.
  • 0003-0215 Daklinza 60 mg Oral Tablet by E.r. Squibb & Sons, L.L.C.

Other drugs which contain Daclatasvir or a similar ingredient: (1 result)